Australia is still aiming to start vaccinating high-risk groups from March. Why the delay?
A nurse prepares a shot for a clinical trial of a COVID-19 vaccine candidate developed by the National Institutes of Health and Moderna Inc., on July 27, 2020 in Binghamton, N.Y.
(AP Photo/Hans Pennink, File)
With COVID-19 vaccine announcements making headlines, non-scientists need to know what clinical trial results mean. Here are some key points to look for in vaccine trial reports.
Unprecedented efforts are driving the global push for a safe and effective vaccine. If and when we have one (or more), here’s how it’s likely to be rolled out in Australia.
Vaccines do more than just protect against the disease they were designed for. They also have so-called non-specific effects that can improve overall health.
Rumor has it that Marcus Rashford and members of royal family will help with the NHS vaccine rollout campaign.
Jose Breton- Pics Action/Shutterstock
We’re on the road again. Getting enough COVID-19 vaccine to where it’s needed in a given time frame is the next logistical hurdle.
Teaching researchers and scientists communication skills — including social media proficiency — will help inform the public about new discoveries and research.
(Shutterstock)
Budget cuts and outsourcing content have affected the amount and quality of science journalism. Scientists should learn to communicate their own findings directly and clearly to the public.
There is now a third vaccine that prevents COVID-19 infections. It isn’t quite as effective as the other two vaccines but it has advantages that may make it the frontrunner.
COVID-19 vaccines are at risk of being undermined by vaccine hesitancy. Pharma must take steps to ensure transparency in data monitoring committees and trial data to build public trust in vaccines.
Mink can be readily infected with SARS-CoV-2 and then pass the virus to humans.
(Shutterstock)
In the disturbing scenario of human-to-mink-to-human COVID-19 transmission, the virus may mutate in mink prior to re-infecting people. That possibility makes vaccine design even more crucial.
The pandemic rages as the world waits for COVID-19 vaccines.
Peter Zelei Images/Getty Images
Because Pfizer-BioNTech and Moderna vaccines have been developed in record time, many wonder whether companies cut corners or compromised safety.
While it may be deflating, events like the annual Macy’s Thanksgiving Day Parade are best watched from home this year. Here, the Harold the Fireman balloon lies face down as he readied for the parade on Nov. 27, 2019.
Gary Hershorn via Getty Images
Inaction over the next few months could cost tens of thousands of lives. Here are things you should do now to stay safe and to stop the spread of the coronavirus.
Pfizer and BioNTech have announced 95% efficacy for their mRNA vaccine, having met the final target they need to before seeking regulatory approval.
A volunteer gets an injection of Moderna’s possible COVID-19 vaccine on July 27, 2020. Moderna announced Nov. 16 that its vaccine is proving highly effective in a major trial.
(AP Photo/Hans Pennink)
Two pharma companies have announced early COVID-19 vaccine trial results with over 90 per cent effectiveness. What does that mean for getting back to normal?
Asking these four questions can help us identify good news when we see it, be more critical of news reports, or delay our judgement until we have more information.
Dean Faculty of Health Sciences and Professor of Vaccinology at University of the Witwatersrand; and Director of the SAMRC Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand